参考文献/References:
[1]Wang Y,Wang X,Lau WB,et al.Adiponectin inhibits tumor necrosis factor-alpha-induced vascular inflammatory response via caveolinmediated ceramidase recruitment and activation[J].Circ Res,2014,114(5):792-805.
[2]Ndrepepa G,Tiroch K,Fusaro M,et al.5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction[J].Journal of the American College of Cardiology,2010,55(21):2383-2389.
[3]Poon K,Seth M,Dixon S,et al.The clinical implications and predictors of no reflow phenomenon in contemporary PCI:Insights from blue cross blue shield of Michigan cardiovascular collaborative Bmc2[J].J Am Coll Cardiol,2013,61(10):e133.
[4]Soeda T,Higuma T,Abe N,et al.Morphological predictors for no reflow phenomenon after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction caused by plaque rupture[J].European Heart Journal Cardiovascular Imaging,2017,18(1):103-110.
[5]Gibson CM,Schomig A.Coronary and myocardial angiography:angiographic assessment of both epicardial and myocardial perfusion[J].Circulation,2004,109(25):3096-3105.
[6]Gavin JB,Maxwell L,Edgar SG.Microvascular involvement in cardiac pathology[J].J Mol Cell Cardiol,1998(30):2531-2540.
[7]Klein LW,Kern MJ,Berger P,et al.Society of cardiac angiography and interventions:suggested management of the no-reflow phenomenon in the cardiac catheterization laboratory[J].Catheter Cardiovasc Interv,2003,60(2):194-201.
[8]Zhao S,Qi G,Tian W,et al.Effect of intracoronary nitroprusside in preventing no reflow phenomenon during primary percutaneous coronary intervention:a meta-analysis[J].J Interv Cardiol,2014,27(4):356-364.
[9]Su Q,Li L,Naing KA,et al.Safety and effectiveness of nitroprusside in preventing no-reflow during percutaneous coronary intervention: a systematic review[J].Cell Biochem Biophys,2014, 68(1):201-206.
[10]Xing K,Fu X,Jiang L,et al.Cardioprotective Effect of Anisodamine Against Myocardial Ischemia Injury and its Influence on Cardiomyocytes Apoptosis[J].Cell Biochemistry & Biophysics,2015,73(3):707-716.
[11]Niu X,Zhang J,Bai M,et al.Effect of intracoronary agents on the no-reflow phenomenon during primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction:a network meta-analysis[J].BMC Cardiovasc Disord,2018,18(1):3.
[12]Bai S,Fu X,Gu X,et al.Intracoronary administration of different doses of anisodamine in primary percutaneous coronary intervention:protective effect in patients with ST-segment elevation myocardial infarction[J].Coronary Artery Disease,2016,27(4):302-310.
[13]Niccoli G,Rigattieri S,De Vita MR,et al.Open-label,randomized,placebo-controlled evaluation of intracoronary adenosine or nitroprusside after thrombus aspiration during primary percutaneous coronary intervention for the prevention of microvascular obstruction in acute myocardial infarction:the REOPEN-AMI study (Intracoronary Nitroprusside Versus Adenosine in Acute Myocardial Infarction)[J].JACC Cardiovasc Interv,2013,6(6):580-589.
[14]Polimeni A,De Rosa S,Sabatino J,et al.Impact of intracoronary adenosine administration during primary PCI:A meta-analysis[J].Int J Cardiol,2016(203):1032-1041.
[15]Nazir SA,McCann GP,Greenwood JP,et al.Strategies to attenuate micro-vascular obstruction during P-PCI: the randomized reperfusion facilitated by local adjunctive therapy in ST-elevation myocardial infarction trial[J].Eur Heart J,2016,37(24):1910-1919.
[16]Feng C,Han B,Liu Y,et al.Effect of nicorandil administration on myocardial microcirculation during primary percutaneous coronary intervention in patients with acute myocardial infarction[J].Postepy Kardiol Interwencyjne,2018,14(1):26-31.
[17]Yamada K,Isobe S,Ishii H,et al.Impacts of nicorandil on infarct myocardium in comparison with nitrate: assessed by cardiac magnetic resonance imaging[J].Heart & Vessels,2015,3(9):1430-1437.
[18]齐琪,陈涛,牛竞辉,等.冠状动脉靶血管内注射尼可地尔对急性ST段抬高型心肌梗死患者急诊经皮冠状动脉介入治疗术中无复流现象的预防效果研究[J].中国全科医学,2017,20(23):2832-2837,2847.
[19]Soukoulis V,Boden WE,Smith SC,et al.Nonantithrombotic medical options in acute coronary syndromes: old agents and new lines on the horizon[J].Circ Res,2014,114(12):1944-1958.
[20]Wang L,Cheng Z,Gu Y,et al.Short-Term Effects of Verapamil and Diltiazem in the Treatment of No Reflow Phenomenon:A Meta-Analysis of Randomized Controlled Trials[J].Biomed Res Int,2015(2015):382086.
[21]Abdelaziz HK,Elkilany W,Khalid S,et al.Efficacy and safety of intracoronary verapamil versus sodium nitroprusside for the prevention of microvascular obstruction during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction[J].Coron Artery Dis,2017,28(1):11-16.
[22]Abu Arab T,Rafik R,El Etriby,A.Efficacy and Safety of Local Intracoronary Drug Delivery in Treatment of No-Reflow Phenomenon: A Pilot Study[J].J Interv Cardiol,2016,29(5):496-504.
[23]Kolh P,Windecker S,Alfonso F,et al.2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI)[J].Eur Heart J,2014,46(4):517-592.
[24]Ali-Hasan-Al-Saegh S,Mirhosseini SJ,Shahidzadeh A,et al.Appropriate bolus administration of glycoprotein Ⅱb/Ⅲa inhibitors for patients with acute coronary syndromes undergoing percutaneous coronary intervention:intracoronary or intravenous? A comprehensive and updated meta-analysis and systematic review[J].Kardiol Pol,2016,74(2):104-118.
[25]Sun B,Liu Z,Yin H,et al.Intralesional versus intracoronary administration of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention in patients with acute coronary syndromes:A meta-analysis of randomized controlled trials[J].Medicine (Baltimore),2017, 96(40):e8223.
[26]Aksu T,Guler TE,Colak A,et al.Intracoronary epinephrine in the treatment ofrefractory no-reflow after primary percutaneous coronary intervention: aretrospective study[J].BMC Cardiovascular Disorders,2015,15(1):10.
[27]Zhang CJ,Deng YZ,Lei YH,et al.The mechanism of exogenous adiponectin in theprevention of no-reflow phenomenon in type 2 diabetic patients with acutemyocardial infarction during PCI treatment.[J].Eur Rev Med PharmacolSci,2018,22(7):2169-2174.
相似文献/References:
[1]何 丽.应激性高血糖与急性心肌梗死的机制研究[J].医学信息,2022,35(10):74.[doi:10.3969/j.issn.1006-1959.2022.10.018]
HE Li.Mechanism of Stress Hyperglycemia and Acute Myocardial Infarction[J].Journal of Medical Information,2022,35(04):74.[doi:10.3969/j.issn.1006-1959.2022.10.018]
[2]赵新娜,吕晓春,任艳琴.PCI术后患者院外康复技能教育的研究[J].医学信息,2018,31(12):170.[doi:10.3969/j.issn.1006-1959.2018.12.054]
ZHAO Xin-na,LV Xiao-chun,REN Yan-qin.The Study of Postoperative Out-of-hospital Rehabilitation Skills Education for Patients after PCI[J].Journal of Medical Information,2018,31(04):170.[doi:10.3969/j.issn.1006-1959.2018.12.054]
[3]雷 锐,李 志.冠状动脉介入及替罗非班治疗老年急性心肌梗死并
心源性休克的疗效分析[J].医学信息,2018,31(14):150.[doi:10.3969/j.issn.1006-1959.2018.14.046]
LEI Rui,LI Zhi.Effect of Coronary Intervention and Tirofiban on Elderly Patients with Acute Myocardial Infarction and Cardiogenic Shock[J].Journal of Medical Information,2018,31(04):150.[doi:10.3969/j.issn.1006-1959.2018.14.046]
[4]杜依浓.经桡动脉与股动脉途径介入治疗老年冠心病患者的疗效及安全性比较[J].医学信息,2022,35(12):172.[doi:10.3969/j.issn.1006-1959.2022.12.043]
DU Yi-nong.Comparison of Efficacy and Safety of Interventional Therapy through Radial Artery and Femoral Artery in Elderly Patients with Coronary Heart Disease[J].Journal of Medical Information,2022,35(04):172.[doi:10.3969/j.issn.1006-1959.2022.12.043]
[5]杨 震.急性心梗直接介入治疗术中慢血流及无复流的治疗进展[J].医学信息,2019,32(06):56.[doi:10.3969/j.issn.1006-1959.2019.06.19]
YANG Zhen.Progress in the Treatment of Slow Blood Flow and no Reflow in the Treatment of Acute Myocardial Infarction[J].Journal of Medical Information,2019,32(04):56.[doi:10.3969/j.issn.1006-1959.2019.06.19]
[6]马洪俊.冠状动脉左主干病变的治疗研究[J].医学信息,2019,32(14):42.[doi:10.3969/j.issn.1006-1959.2019.14.015]
MA Hong-jun.Study on the Treatment of Left Main Coronary Artery Disease[J].Journal of Medical Information,2019,32(04):42.[doi:10.3969/j.issn.1006-1959.2019.14.015]
[7]邓 伟.血必净注射液预防STEMI患者直接介入治疗后冠脉无复流的效果[J].医学信息,2020,33(17):163.[doi:10.3969/j.issn.1006-1959.2020.17.049]
DENG Wei.Effect of Xuebijing Injection in Preventing Coronary Artery No-reflow After Direct Interventional Therapy in STEMI Patients[J].Journal of Medical Information,2020,33(04):163.[doi:10.3969/j.issn.1006-1959.2020.17.049]
[8]张亦晗,刘晓戈,喻玲玲,等.中青年经皮冠状动脉介入治疗术后患者配偶照顾者疾病获益感现状及影响因素分析[J].医学信息,2023,36(03):53.[doi:10.3969/j.issn.1006-1959.2023.03.012]
ZHANG Yi-han,LIU Xiao-ge,YU Ling-ling,et al.Analysis of the Status Quo and Influencing Factors of Perceived Caregiving Benefits of Spouse Caregivers of Young and Middle-aged Patients After Percutaneous Coronary Intervention[J].Journal of Medical Information,2023,36(04):53.[doi:10.3969/j.issn.1006-1959.2023.03.012]
[9]曹培东,桂 春.PCI对RelA的影响及血运重建后的作用机制研究[J].医学信息,2022,35(08):74.[doi:10.3969/j.issn.1006-1959.2022.08.018]
CAO Pei-dong,GUI Chun.Effect of PCI on RelA and its Mechanism After Revascularization[J].Journal of Medical Information,2022,35(04):74.[doi:10.3969/j.issn.1006-1959.2022.08.018]